MarketLens
Sign Up

Ionis Pharmaceuticals: A Director's $1 Million Bet Against the Bear

1 months ago
SHARE THIS ON:

Ionis Pharmaceuticals: A Director's $1 Million Bet Against the Bear

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 months ago

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Ionis Pharmaceuticals director Hayden bought 20,000 shares for ~$1.1 million, raising his direct and indirect holdings by 34%, signaling insider confidence.
Stock News2 months ago

Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up

Ionis Pharmaceuticals shares fell 9% intraday to ~$58.30 from a $64.27 open, as negative news continues to accumulate.
Stock News2 months ago

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

Biogen is paying ~$1B for an undisclosed immunology asset, strengthening its pipeline after a blockbuster lost exclusivity. The deal signals a strategic pivot toward growth in a key therapeutic area.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

BABA 13-DAY DEADLINE ALERT: Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 5, 2026 Lead Plaintiff Deadline

Stock News2 hours ago

Nasdaq Scores Record As Oil Eases; Apple Tests Buy Point

Stock News2 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alibaba Group Holding Limited of Class Action Lawsuit and Upcoming Deadlines – BABA

Stock News2 hours ago

Meta Was the Worst AI Lab

Stock News3 hours ago

Why Apple could soon join Nvidia in the exclusive $5 trillion club